Navigation Links
Warning on Avastin Updated

A new label change has been proposed by the FDA for the anti-angiogenic colorectal-cancer drug Avastin (bevacizumab) to include rare cases of a reversible posterior leukoencephalopathy syndrome in its warning.//

Genentech, which markets Avastin said that the brain-capillary leak syndrome has been reported or confirmed in less than 0.1% of the estimated 60,000 cancer patients treated with Avastin.

The Adverse Reactions and Dosage and Administration sections of the Avastin label have been updated to include the warning about reversible posterior leukoencephalopathy as well as nasal septum perforation.

Genentech reported seven cases of nasal septum perforation reported in post market surveillance.

Reversible posterior leukoencephalopathy syndrome is also associated with fluid retention, hypertension and the cytotoxic effects of the immunosuppressive drugs on the vascular endothelium.

J. Leonard Lichtenfeld, M.D., deputy medical director of the American Cancer Society in Atlanta, said this not the first time that the anti-angiogenic agent has been linked with bleeding problems. He noted, for example, the perforated colon has been reported in Avastin colorectal cancer studies.

Dr. Lichtenfeld said, "This is exactly the reason that post marketing surveillance is so important for all drugs and especially for chemotherapy drugs."

According to him Avastin is "typically is given to patients with advanced disease and aggressive tumors," a patient population that is compromised by disease and thus at higher risk for side-effects.

Genetech letter’s to the clinicians said that reversible posterior leukoencephalopathy usually presents with "headache, seizure, visual disturbance, and altered mental function, and is characterized by reversibility upon control of hypertension or other instigating factors," with onset of symptoms reported to occur within 16 hours to one year of initiation of Avastin treat ment.

Magnetic resonance imaging studies are needed to confirm diagnosis.

Patients who develop symptoms of reversible posterior leukoencephalopathy should discontinue Avastin and initiate hypertension treatment, if necessary.

Genetech also says that symptoms "usually resolve or improve within days, although some patients have experienced ongoing neurologic sequelae." It is still unknown however whether Avastin can safely be reinitiated in patients who developed reversible posterior leukoencephalopathy syndrome.


Related medicine news :

1. Early Warning System For Breast Cancer
2. Warning on radiowave exposure
3. A Seizure Late In Life Could be A Stroke Warning
4. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
5. Early Warning Signs Of Heart Disease
6. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
7. Warning issued by FDA over "Liqiang 4 Capsules"
8. Warning Signs On Powered Baby Milk
9. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
10. Global Outbreak Of Bird Flu Warning By Chinese Scientist
11. Experts Building Bird Flu Warning System
Post Your Comments:

(Date:11/30/2015)... , ... November 30, 2015 , ... At Grand Dental ... and convenient setting. , When you have dental problems, you need to turn to ... can effectively diagnose and treat your needs, a friendly dentist who counsels you on ...
(Date:11/30/2015)... ... , ... Using a combination of two blood sugar tests rather than a ... a new study by researchers at the School of Public Health at Georgia State ... of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers noted ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly ... out of Glen Ridge, NJ. He has both advanced training and considerable ... He is also an expert in cosmetic dentistry. He is an active ...
(Date:11/30/2015)... ... 2015 , ... International telepathology consultations can significantly improve patient ... Diagnostics researchers. Their review of more than 1,500 pathology cases submitted electronically ... significantly altered treatment plans for more than half of the cases in which ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ”Dying Words: The ... be released on December 1, 2015, to coincide with World AIDS Day. The multi-media ... journalist who covered the AIDS epidemic as he was dying of the disease. , ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015  IBA Molecular North America, Inc. (IBAMNA), ... radiopharmaceuticals, announced that as of January 1, 2016, it ... The decision to rebrand the company reflects a refined ... as its close relationship with Zevacor Molecular.  Both IBAMNA ... Science (IHS). Peter Burke , Vice ...
(Date:11/30/2015)... , November 30, 2015 North ... and is expected to grow at a CAGR of 7.6% from ... was valued at USD 135.6 million in 2014, and is expected ... --> According to the new Market Research Report "North ... non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis And ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology: